Dahlöf B, Hansson L, Lindholm L, Schersten B, Wester P O
Department of Medicine, Ostra Hospital, University of Gothenburg, Sweden.
J Hypertens Suppl. 1987 Dec;5(5):S607-10.
The Swedish trial in old patients with hypertension (STOP-Hypertension) is a multicentre, randomized, double-blind study of beta-blockers/diuretics versus placebo in old hypertensives. Primary end-points are stroke and myocardial infarction (fatal and non-fatal) as well as other cardiovascular mortality. To evaluate the logistics of STOP-Hypertension, a pilot study was carried out. All patients aged 70-84 years in 31 centres were consecutively registered in a log-book. Altogether 4668 patients were screened: 41.5% had previously been treated for hypertension and 13.5% had blood pressures greater than or equal to 180/105 mmHg. Thus, 55% were 'hypertensive'. In all, 465 patients (18% of the 'hypertensive' patients) started a 3-month washout period (previously treated, n = 396) or a 4-week run-in period (previously untreated, n = 69) period. The most frequent reasons for not starting the run-in/washout were other indications for treatment with beta-blockers/diuretics (13%), unwillingness to participate (8%) or isolated systolic hypertension (4%). The pilot study was evaluated after 1 year: 89 patients (1.9%) had been randomized, 66 patients (1.4%) were still in the run-in/washout period and the majority of the remaining patients were not randomized because they had not reached the inclusion blood pressure (greater than or equal to 180 mmHg systolic and/or greater than or equal to 105 mmHg diastolic) following withdrawal of their antihypertensive medication. During the run-in/washout period there were few serious clinical events: one case of myocardial infarction, three patients had strokes (two fatal), 10 developed congestive heart failure, three tachyarrhythmia and two pneumonia (one fatal).(ABSTRACT TRUNCATED AT 250 WORDS)
瑞典老年高血压患者试验(STOP - 高血压试验)是一项多中心、随机、双盲研究,对比β受体阻滞剂/利尿剂与安慰剂在老年高血压患者中的疗效。主要终点为中风、心肌梗死(致命性和非致命性)以及其他心血管疾病死亡率。为评估STOP - 高血压试验的后勤安排,开展了一项试点研究。31个中心的所有70 - 84岁患者连续登记在一本日志中。共筛查了4668名患者:41.5%既往接受过高血压治疗,13.5%的患者血压大于或等于180/105 mmHg。因此,55%为“高血压患者”。共有465名患者(占“高血压”患者的18%)开始了为期3个月的洗脱期(既往接受治疗者,n = 396)或为期4周的导入期(既往未接受治疗者,n = 69)。未开始导入/洗脱期的最常见原因是有β受体阻滞剂/利尿剂治疗的其他指征(13%)、不愿参与(8%)或单纯收缩期高血压(4%)。1年后对试点研究进行评估:89名患者(1.9%)已随机分组,66名患者(1.4%)仍处于导入/洗脱期,其余大多数患者未随机分组是因为在停用抗高血压药物后未达到纳入血压标准(收缩压大于或等于180 mmHg和/或舒张压大于或等于105 mmHg)。在导入/洗脱期,严重临床事件较少:1例心肌梗死,3例患者中风(2例致命),10例发生充血性心力衰竭,3例发生快速性心律失常,2例发生肺炎(1例致命)。(摘要截选至250字)